[HONG KONG, January 25, 2022] Great Bay Bio Group Limited (hereinafter referred to as “GBB”), an AI-enabled biotechnology company, announced today that it has formed a strategic alliance with ChemPartner, further strengthening both company’s value proposition to prospective clients in the biopharmaceutical industry.

GBB is a high-tech enterprise dedicated to applying artificial intelligence and other cutting-edge technologies to the development of biopharmaceuticals. ChemPartner is an enterprise aiming to provide comprehensive CDMO services to global pharmaceutical and biotechnology companies. The two sides have reached strategic alliance in Greater China Area in order to combine GBB’s AI-enabled CDO development platform and ChemPartner’s comprehensive biological drug CDMO capabilities. This strategic alliance aims to provide an AI-enabled, one-stop CMC solution to prospective clients, quickly and efficiently completing projects through high-quality cooperation of both companies. Through this strategic alliance, GBB can now can offer clients downstream development capabilities, such as process development, big quantity GMP pilot manufacturing, and IND package submission.

GBB has three commercial AI-enabled bioprocessing development platforms, including AI-enabled cell line development platform Klone4.0™, AI-enabled cell line stability prediction platform AlfaStaX^® and AI-enabled culture media development platform AlfaMedX^®. AI technology holds the key to reduce repetitive labor, reduce the screening time and greatly improve the success rate and stability of cell line screening in the process of cell line development.

Dr. Chen Liang, founder and CEO of GBB, said, “We are thrilled that we have reached the strategic alliance with ChemPartner. ChemPartner has cGMP level CDMO section production facilities and rich domestic and international IND application experience. Meanwhile, GBB owns strong innovation ability in biopharmaceuticals CDO phase, which mutually reinforcing with ChemPartner. Through this strategic alliance, GBB can strengthen our ability to provide customers with full value chain CDMO and domestic and international IND application. GBB has set up a complete closed-loop system of technology development, product development, product production and commercial transformation, making global bioprocessing simpler and more efficient.”

Dr. Xiang Ju, general manager of China Gateway Biologics, a subsidiary of ChemPartner, comments, “ChemPartner has complete R&D and production capacity for biological drugs from early discovery to commercial production. In the past few years, we have helped our customers successfully obtain IND clinical approvals from 14 NMPA and 8 FDA. We are very pleased to reach strategic alliance with Great Bay Bio. We hope that the bioprocessing development could be improved with GBB’s AI-enabled technology development platforms, greatly to improve the R&D efficiency and yield and quality of drugs, as well as to reduce the development cycle and costs. We will help customers bring innovative biological drugs to the clinic faster and better.”

About ChemPartner

Shanghai ChemPartner Co., Ltd. (ChemPartner) is a world leading scientific research outsourcing service organization (CRO + CDMO business), founded in 2002. Adhering to the service concept of innovation driven and customer first, ChemPartner is dedicated to providing comprehensive and high-quality new drug R&D services for global pharmaceutical companies and biotechnology companies. Chempartner business covers all aspects of new drug R&D, such as early antibody R&D, pharmacological efficacy, pharmacokinetics and early toxicology, biological drug process development, GMP pilot test and commercial production. ChemPartner provides customers with integrated new drug R&D and production outsourcing services. It has served more than 1000 domestic and foreign pharmaceutical enterprises and biomedical technology companies, among which top 20 pharmaceutical and biotechnology enterprises in the world.